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As we celebrate the 40th anniversary of the American 
College of Cardiology, it is fascinating to note the progress 
that has occurred over the past 40 years in our understand- 
ing of the pathophysiology of coronary artery disease as 
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Treatment objectives. As is ideal in all physician-patient 
well as its treatment. Appreciation of the ex- 
traordinary change in the emphasis and ap- 
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preach to coronary artery disease from 1949 to * * * * * - * * * - 
1989 is provided by review of the Quarterly : : 
Cumulative Index Medicus of 1949. A total . 
of 31 papers are referenced under the topic 
“angina pectoris and its therapy.” Of these. 
six deal with the use of methylthiouracil or A N N , v E R s A R y 
thyroidectomy in treatment of angina (I-6). , 9 4 9 _ 
interactions that result in diagnostic or therapeu- 
tic strategy decisions, a clear objective for each 
intervention needs to be enunciated. Treatment 
objectives include I) symptom relief with a 
minimum of side effects: 2) enhancement of 
event-free survival; and 3) risk factor control 
with the objective of reducing progression in the 
basic disease process. 
seven report on surgical resection or local _ _ 
injection therapy of the stellate ganglia or aortic nerve plexus 
(7-14) and two report on experience with vitamin E (15,16). 
One additional reference cites what must be one of the 
earliest placebo-controlled trials in evaluating chest pain 
(17). 
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The contrast with today’s Index Medicus in terms of 
volume of studies and approach to coronary disease is 
readily apparent. The advances have been remarkable 
and associated with a major decline in coronary heart 
disease mortality (18). Although the basis for this decline 
is undoubtedly multifactorial, with fascinating geographic 
variations (19). there seems little doubt that treatment 
has played a role (20). The object of this article is to 
provide a review of current approaches to treatment of 
specific clinical subsets of patients with coronary artery 
disease. 
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Risk stratification. The clinician planning 
therapy for an individual patient must first es- 
tablish an accurate clinical profile of the patient in terms of 
symptoms, functional disability, quality of life and risk for 
subsequent cardiac events. The most important means to 
establish such a fundamental clinical profile are the history 
and physical examination. After these are accomplished, it 
may be appropriate to proceed with selective noninvasive 
testing to assess prognosis in mildly symptomatic patients or 
to proceed directly to coronary arteriography in patients 
with severe or unstable symptoms. Some patients will not 
require further testing. The approach selected should be 
based on a clearly stated objective and a pretest review of 
how the test result will influence decision making. Funda- 
mental to risk stratification is the recognition that left ven- 
tricular function is the most powerful predictor of survival 
(21,221. Simply acquired clinical and rest electrocardio- 
graphic (ECG) variables contain important prognostic infor- 
This article is part oftr series of articles celebrating 
the 40th unniversary of the American College of 
Cardiology. The series attempts to set the stage for the 
.future by describing current stale of the art manage- 
ment of selected major cardiovascular problems and 
the basic knowledge that w?ill provide directions .for 
advances in diagnosis and therapy. 
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mation, in part because they reflect left ventricular function 
(23-25). The incremental value of any additional testing 
should be carefully considered before further testing is 
performed (26). 
Stable Angina Pectoris 
Once the clinician has established the presence of angina 
pectoris by history and identified other complicating medical 
conditions, an assessment of functional impairment and risk 
for subsequent cardiac events is necessary. It is impossible 
to include all possible scenarios that might influence decision 
making. For an elderly patient with no strenuous demands in 
work or recreation, a trial of medical therapy may be 
appropriate without other testing. For patients with severe 
disabling symptoms, particularly those already on medical 
therapy, coronary arteriography without other testing is 
necessary to define suitability for coronary revascularization 
with either coronary angioplasty or coronary artery bypass 
grafting. Controlled clinical studies have documented 1) the 
relief of angina pectoris with bypass surgery (27-29), and 2) 
improvement in objective indexes of functional capacity and 
myocardial ischemia (30,31). In the large randomized trials, 
coronary bypass surgery was demonstrated to be more 
effective than standard medical therapy alone in relief of 
angina. However, that advantage diminishes after several 
years as a result of graft occlusion and progression of native 
coronary artery disease. 
Coronary angioplasty. The transluminal approach to 
treating coronary artery disease was introduced with coro- 
nary angioplasty (32). This technique results in sustained 
improvement in the majority of appropriately selected pa- 
tients (33), with low morbidity and little time away from 
work (34). In patients with multivessel disease, event-free 
outcomes are more frequent in those with “complete” 
revascularization (35). An American College of Cardiology/ 
American Heart Association Task Force recently empha- 
sized that “the approach to every angioplasty procedure 
requires a knowledgeable judgment that weighs the likeli- 
hood of a successful outcome against the likelihood of failure 
and the risk of complications” (36). It is important to note 
the lack of published controlled studies of coronary angio- 
plasty versus other therapies in relief of angina pectoris. 
Although there are abundant published observational data to 
support the effectiveness of coronary angioplasty in relief of 
myocardial ischemia, presumption of applicability of the 
results of bypass surgery to treatment with angioplasty is 
unwarranted. 
Role of stress testing in assessing prognosis. Stress testing 
for the purpose of assessing prognosis is appropriate in 
physically active persons with mild angina and normal 
ventricular function. Several studies have documented the 
prognostic value of exercise ECG testing (37,38), radionu- 
elide ventriculography at rest and with exercise (39-41) and 
stress thallium studies (42,43). Whereas ambulatory moni- 
toring for silent ischemia has been shown to contain impor- 
tant prognostic information in highly selected patients (44- 
46), its use as a general screening technique in patients at low 
risk for coronary artery disease in clinical practice has not 
been established (47). Profound early ischemia with standard 
stress tests identifies patients at relatively high risk of a 
subsequent cardiac event and coronary arteriography is 
indicated. This inference is based on evidence from random- 
ized trials and observational data base studies documenting 
improved survival of specific angiographic subgroups of 
patients with stable angina treated with coronary bypass 
surgery rather than an initial strategy of medical therapy. 
These studies have emphasized a consistent trend: the 
higher the risk for subsequent events based on anatomy, left 
ventricular function and severity of myocardial ischemia, the 
greater the degree of benefit from coronary artery bypass 
surgery as compared with medical therapy. Therefore, def- 
inition of coronary anatomy and left ventricular global 
function is necessary in patients with mild symptoms and 
profound ischemia on stress testing if the patient is a 
candidate for bypass surgery from a general medical point of 
view. 
Indication for surgery or angioplasty. Patients with an- 
gina pectoris associated with >50% luminal diameter nar- 
rowing of the left main coronary artery (48) or triple vessel 
disease and abnormal left ventricular function are generally 
believed to have better survival with surgery as compared 
with medical therapy (28,49-53). In the Coronary Artery 
Surgery Study (CASS) randomized trial, no difference in 
survival of patients with mild angina and three vessel disease 
with normal left ventricular function (or single or double 
vessel disease) was observed in those randomized to an 
initial strategy of medical therapy compared with those 
randomized to coronary bypass surgery (54). This observa- 
tion emphasizes the importance of studies that have docu- 
mented the value of risk stratification in patients with triple 
vessel coronary artery disease to define those with a major 
benefit in survival with bypass surgery (55,56). There are 
data to support surgical treatment of patients with two vessel 
disease who have severe angina in association with de- 
pressed left ventricular function (57). 
Invasive therapy (surgery or angioplasty) is reserved for 
patients with single vessel disease and disabling symptoms 
or those with a large area of myocardium at jeopardy with 
documentation of early profound ischemia on stress testing. 
Revascularization may be necessary in some patients with 
single and double vessel disease for control of angina pec- 
toris or protection of large areas of myocardium from 
subsequent myocardial infarction. However, with the in- 
creasing confidence in coronary angioplasty, more patients 
with single and double vessel disease are coming to angio- 
plasty with less convincing indications. The restenosis rates 
associated with angioplasty (58,59) should temper enthusi- 
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Figure 1. Isolated coronary bypass operations at the Mayo Clinic 
and average age of patients by year (1972 through 1986 inclusive). 
asm for an aggressive approach with angioplasty based 
solely on anatomic findings in patients at low risk for 
subsequent events. Most approaches to prevent restenosis 
have failed (60) and a recent report (61) on the use of fish oil 
in reducing restenosis needs further study. If the risk for 
subsequent cardiac events is low in an individual patient, 
successful accomplishment of angioplasty, while technically 
satisfying in the short term, may not be in the best interests 
of the patient. Although criticism from cardiologists regard- 
ing surgical treatment of single vessel disease was frequent 
before angioplasty was available, less is said now that the 
therapy can be accomplished with coronary angioplasty. 
Aggressive invasive treatment of any kind seems doomed 
to failure if the symptoms are not clearly related to myocar- 
dial ischemia (62). Use of angioplasty in patients without 
definite angina and myocardial ischemia often results in 
patients with recurrent chest pain, and the multiple subse- 
quent angiographic studies performed to clarify coronary 
anatomy result in continuing disability and large medical and 
emotional costs. The same can of course be said of inappro- 
priately applied coronary bypass surgery. 
Cost of surgery. Because of the large volume and ex- 
pense of coronary bypass operations, the procedure remains 
under close scrutiny in the era of cost containment. It is 
estimated that in 1986 well over 200.000 coronary bypass 
procedures were performed (63). An increasing proportion 
of operations are performed in elderly patients (Fig. 1) and 
those requiring reoperation. The appropriateness of bypass 
surgery has thus been the subject of considerable debate and 
study. In one study. Winslow et al. (64) studied the appro- 
priateness of surgery in three randomly selected hospitals in 
the western United States. In this small sample of patients 
(n = 386), only 56% of patients were considered “appro- 
priate” for coronary bypass surgery by an expert panel. 
Although this consideration is unfortunate, it demonstrates 
the need for professional education and guidelines for ther- 
apy. When appropriately applied, bypass surgery has been 
demonstrated to be a highly cost effective therapy (65). 
Internal mammary versus vein grafts. Although antiplate- 
let therapy before and after operation improves aortocoro- 
nary vein graft patency (66). there remains a major problem 
with long-term results of vein graft conduits for relief of 
myocardial ischemia (67). Loop et al. (68) and others have 
demonstrated that improved late patency of the internal 
mammary artery increases patient survival over that in 
patients who receive only saphenous vein grafts. The clini- 
cally documented advantages of internal mammary artery 
versus vein grafting have a physiologic basis as proposed by 
Luescher et al. (69). The importance of internal mammary 
artery grafting is further emphasized by the late follow-up 
data on surgically treated patients in the early large random- 
ized trials with vein grafts as conduits (70,71), which re- 
vealed a decline in survival advantages of surgical therapy 
after 5 to 8 years. These data emphasize the need for careful 
yearly surveillance of patients after bypass surgery. Equally 
important i5 the yearly follow-up of patients treated medi- 
cally. 
Medical treatment. If medical treatment is deemed ap- 
propriate for treatment of angina pectoris. the clinician has 
three classes of drugs available for control of angina pec- 
toris. These are beta-adrenergic blockers, calcium channel 
entry blockers and nitrates. The choice of these drugs or 
their use in combination is based on the individual charac- 
teristics of the patient (72). Long-acting nitrates may be 
effective in patients with mild angina, particularly in those 
who are relatively inactive. There may be a great cost 
advantage for nitrates if symptom relief is the only objective. 
Physicians using nitrates must be aware not only of the 
pharmacology of the multiple products available but also the 
cost implications of the various modes of administration. 
Considering the tolerance issue with long-term administra- 
tion of nitrates, an oral preparation used two to three times 
daily may have advantages for most patients. However. in 
more active patients with coexistent hypertension, drugs 
that control blood pressure and heart rate may optimize the 
relation between myocardial oxygen demand and supply. A 
major advance in our understanding of the pathophysiology 
of angina pectoris occurred with the observations of Chier- 
chia et al. (73) documenting the importance of vasoactivity 
of the coronary circulation in patients with coronary artery 
disease. thus challenging the dogma that myocardial oxygen 
demand is the most important determinant of myocardial 
ischemia. This concept provided new approaches for medi- 
cal therapy (74). The theoretical and objective documenta- 
tion of beta-blocker efficacy has been indisputably estab- 
lished. Calcium channel blockers have rapidly established 
their place in the therapeutic armamentarium of angina 
pectoris. In patients with variant angina, calcium channel 
blockers and nitrates are the drugs of choice. Enthusiasm for 
the calcium channel blockers as monotherapy has dimin- 
ished. However. their synergistic action with beta-blocker 
drugs may be very helpful, but the increased instance of side 
effects needs to be borne in mind. The effectiveness of 
current drugs individually and in combination to provide 
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relief of angina pectoris has been documented in multiple 
placebo controlled trials (75,76). 
Revascularization procedures. For patients in whom re- 
vascularization is considered appropriate, we still do not 
have data from controlled studies to help choose between 
coronary angioplasty or bypass surgery as the initial therapy 
in patients suitable for either procedure. Fortunately a 
Veterans Administration trial will provide much needed data 
for patients with single and double vessel disease. There are 
other studies comparing angioplasty and surgery in multi- 
vessel coronary artery disease, including the Emory An- 
gioplasty Surgery Trial (EAST), Bypass Angioplasty Re- 
vascularization Investigation (BARI) and several European 
studies. 
Unstable Angina 
It has been known for many years that patients with 
unstable angina are at high risk for subsequent cardiac 
events (77-79). Whereas some investigators (80) have con- 
sidered recent onset angina as an exception to this concept, 
others (81) have provided evidence to support a high risk of 
subsequent events in such patients. Other patterns of rest 
pain with ECG changes seem to identify high risk patients 
(82,83). 
Initial management. The patient who presents with in- 
creasingly severe angina including episodes of pain at rest is 
best treated in the hospital with ECG monitoring. Most 
would agree with an initial effort to provide pain relief with 
medical therapy before proceeding to coronary arteriogra- 
phy. Use of all three classes of antianginal drugs may be 
necessary. Intravenous nitroglycerin combined with a beta- 
blocker represents the first approach unless there is good 
evidence for coronary vasospasm as a primary mechanism. 
In addition to beneficial effects on heart rate and blood 
pressure, beta-blockers have other advantages (84,85). Cal- 
cium channel blockers have also been shown to be effective 
(86,87) but if nifedipine is used, its combination with beta- 
blocking treatment is wise (88). 
Antithromhotic and antiplatelet therapy. Instability of 
atherosclerotic plaques with thrombus formation (89-93) has 
been established as the pathogenesis for this syndrome. 
Thus, it is not surprising that clinical studies are confirming 
an important role for the use of heparin and antiplatelet 
treatment. Fitzgerald et al. (94) demonstrated platelet acti- 
vation in patients with unstable coronary artery disease, and 
we now have two well designed trials (95,96) establishing the 
benefit of aspirin therapy in reducing cardiac mortality and 
other events in patients with unstable angina. Activation of 
the intrinsic coagulation cascade occurs in patients with 
unstable angina and is manifested by elevated fibrinopeptide 
(97). Theroux et al. (98) have also reported a double-blind, 
randomized, placebo-controlled trial showing independent 
beneficial effects of heparin and aspirin in reducing cardiac 
events in the short term (mean of 6 days) in patients with 
unstable angina. Given the role of thrombus in pathogenesis 
of unstable angina, the use of fibrinolytic drugs is receiving 
attention (99) but will require further study in properly 
designed trials. 
Coronary interventions and revascularization. Whereas 
the aspirin trials in patients with unstable angina have 
documented one of the few survival benefits of drug therapy 
in patients with coronary artery disease, most cardiologists 
favor proceeding with coronary angiography early, though 
with a patient in stable condition if possible. Inability to 
stabilize an unstable condition with drugs may require 
mechanical support with intraaortic balloon pumping. Once 
coronary anatomy is defined, a decision on invasive revas- 
cularization therapy is necessary. Suitability of lesions for 
either coronary angioplasty or bypass surgery must be 
decided (36) and then a decision must be made as to 
advisability of proceeding with either on the basis of an 
integration of the likelihood of success, risks and the indi- 
vidual patient profile. Most would base the decision to 
intervene with bypass surgery on accepted anatomic subsets 
of patients as previously described while preferring angio- 
plasty for single vessel or less extensive multivessel disease 
in patients with ongoing symptoms of ischemia who are 
unresponsive to medical treatment. These judgments are 
influenced importantly by the Veterans Administration study 
of bypass surgery in unstable angina (loo), which demon- 
strated a benefit in survival only in patients with a moderate 
decrease in left ventricular function and triple vessel disease. 
In our own practice, revascularization is recommended in 
essentially all clinically and anatomically suitable subsets of 
patients with unstable angina before hospital discharge. 
Although many observational studies (101) have docu- 
mented success rates and problems for coronary angioplasty 
in unstable angina, the assumption that results from surgical 
trials apply to angioplasty is not proved. This problem 
further emphasizes the importance of ongoing clinical trials 
to compare, directly the benefits and adverse effects of an 
initial angioplasty versus surgical strategy in patients with 
unstable angina. 
Myocardial Infarction 
Extraordinary advances have occurred in treating pa- 
tients with myocardial infarction; these have been based on 
redefining the primary pathophysiologic events leading to 
myocardial infarction. Whereas Herrick (102) suggested that 
thrombus has a primary role in causing myocardial infarc- 
tion, others (103) considered most thrombi in the infarct- 
related artery to be secondary events. However, the work of 
Davies and Thomas (92) and Falk (93) reemphasizing the role 
of plaque fissuring leading to acute thrombosis at such sites, 
and the clinical studies of DeWood et al. (104) documenting 
acute coronary thrombosis in the earliest phase of acute 
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Figure 2. Survival data from randomized trials of intravenous 
thrombolytic therapy in acute myocardial infarction. The early 
mortality rate is compared for the treatment group on the vertical 
axis with the placebo group on the horizontal axis. AIMS = APSAC 
Intervention Mortality Study: Asp = aspirin: Eur TPA = European 
TPA: GISSI = Gruppo Italian0 per lo Studio della Streptochinasi 
nell’Infarto Miocardico: ISAM = Intravenous Streptokinase in 
Acute Myocardial Infarction trial; ISIS II = Second International 
Study of Infarct Survival: SK = streptokinase. 
myocardial infarction provided a new stimulus for investiga- 
tion of thrombolytic therapy. 
Thromholytic and antiplatelet therapy. Excellent data 
from clinical trials have now been published documenting 
improved survival after intravenous thrombolytic drug ther- 
apy (105-l 10). In Figure 2 early mortality is compared in the 
placebo versus treatment groups in the large trials of intra- 
venous thrombolytic therapy. There is a consistent trend of 
enhanced survival in patients receiving thrombolytic therapy 
as compared with those receiving placebo. 
In spite of the survival benefit noted in these trials, a 
small but definite increase in reinfarction rates followed 
successful thrombolytic therapy in most trials with use of 
antiplatelet treatment. Figure 3 summarizes a comparison 
between placebo and treatment groups for several of the 
trials of intravenous thrombolytic therapy. Note the reduced 
Figure 3. Early reinfarction rates after intravenous thrombolytic 
therapy in acute myocardial infarction. The treatment group is on 
the vertical axis and the placebo group on the horizontal axis. 
Abbreviations as in Figure 2. 
reinfarction rates in the Second International Study of In- 
farct Survival (ISIS-2) subgroups treated with aspirin alone 
or with combined streptokinase and aspirin. These decreases 
may be the clinical expression of the important observations 
of Fitzgerald et al. (111) documenting platelet activation as 
thrombolysis proceeds after streptokinase. Platelet activa- 
tion with release not only of thromboxane but also of 
serotonin has been reported after thrombolysis with tissue 
plasminogen activator (rt-PA) (112). Activation of coagula- 
tion with thrombolysis has also been reported (113). It 
therefore appears that antiplatelet therapy in conjunction 
with thrombolytic therapy at the onset of acute myocardial 
infarction prevents or reduces platelet activation in this 
setting with a reduction in reinfarction rates. The complex 
nature of the interaction among platelets, ongoing throm- 
bolysis. the actual clot and underlying arterial disease pre- 
sents other possible approaches to therapy (114). 
Combined thrombolysis and angioplasty. With the ob- 
served reinfarction rates (115) and the observed high grade 
residual obstruction evident after successful thrombolysis, a 
rationale for combining coronary angioplasty with intrave- 
nous thrombolysis was proposed. However. data from sev- 
eral trials ( 116-l 18) have consistently shown no advantage in 
routine early angioplasty in the setting of active thrombolytic 
therapy. The place of coronary angioplasty as a primary 
modality to open an infarct-related artery is not settled 
primarily because, except for a study by O’Neill et al. (119), 
we have no controlled studies of angioplasty alone versus 
thrombolytic therapy alone. Angioplasty as primary therapy 
to open infarct-related arteries needs further study because 
20% to 30% of patients presenting with myocardial infarction 
may have contraindication to thrombolytic therapy (105). 
Such patients presenting within 4 h of infarction may benefit 
from mechanical opening of the infarct-related artery. Fea- 
sibility of this approach has been demonstrated in observa- 
tional studies (120,121). as well as by O’Neill et al. (119), 
with an approximately 85% success rate in opening the 
infarct-related artery. Additional advantages may include 
earlier opening of the infarct-related artery with benefit to 
patients in cardiogenic shock and less risk of bleeding 
complications. 
Decision protocol. The physician considering thrombo- 
lytic therapy for a patient with an acute myocardial infarc- 
10 tion must make major decisions decisively and early. First, 
g an accurate diagnosis of myocardial ischemic infarction is 
E: 8- 
Z 
mandatory. Age of the patient remains a difficult issue. No 
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bolytic treatment is 14 h after onset of symptoms, in ISIS-2 
benefit was noted through 24 h after symptom onset, thus 
suggesting an increased time frame for intervention. In 
ISIS-2, however, a significant proportion of the patients did 
not meet criteria for acute myocardial infarction at time of 
randomization and represented patients with unstable myo- 
cardial ischemia or a slowly evolving infarction. The choice 
of a thrombolytic drug is controversial. Increased effective- 
ness in clot lysis has been documented with rt-PA, but 
clinical effectiveness in reducing mortality of acute infarc- 
tion has been proved with both streptokinase and rt-PA. 
Several large randomized trials have been designed to com- 
pare streptokinase versus t-t-PA with respect to survival and 
complications to assess whether the early effects of rt-PA on 
patency will be associated with better survival. 
Other advances in management of acute infarction. Al- 
though thrombolysis and angioplasty have attracted a great 
deal of attention, other extremely important advances in 
managing patients with acute myocardial infarction have 
occurred. Hemodynamic monitoring has played an impor- 
tant role in managing a subset of patients with hemodynamic 
instability (123,124). Intravenous nitroglycerin reduces in- 
farct size (125) and mortality (126), but recognition of the 
problem of nitrate tolerance in prolonged use of the drug is 
essential (127). Approaches with vasoactive drugs to help 
stabilize hemodynamically unstable patients are well estab- 
lished and the recognition of hypovolemia as a cause of 
hypotension in acute infarction has been a major contribu- 
tion of hemodynamic monitoring. The role of left ventricular 
assist devices, as a substitute for intraaortic balloon pump- 
ing, is receiving increased attention, and these may serve as 
a bridge to cardiac transplantation in properly selected 
patients. Another major advance has occurred in recognition 
and management of patients with right ventricular infarction 
(128-130). 
Role of beta-adrenergic blockers. Documentation of im- 
proved survival and reduced reinfarction rates for patients 
with myocardial infarction treated with a beta-blocker is one 
of the most effectively documented effects of drug therapy in 
cardiology (131-133). Although benefit has been observed 
even when therapy is started several days after the acute 
event, recent data (134) support administration of a beta- 
blocker in the acute phase of infarction unless there are 
contraindications to its use. The major benefit appears to 
occur in patients with more complicated myocardial infarc- 
tion (135). Calcium channel blockers have also been tested in 
the setting of Q wave infarction with either no benefit or 
adverse effects (136,137), particularly in patients with a left 
ventricular ejection fraction ~40% (138). In spite of the large 
volume of published data demonstrating the effectiveness of 
beta-blockers in reducing subsequent cardiac events, espe- 
cially sudden death and recurrent infarction, many patients 
who have no contraindication to these agents are still not 
receiving them after an acute infarction. Failure to provide 
this treatment is justified only if the patient is demonstrated 
to be in a low risk category and its occurrence illustrates a 
continuing problem of inadequate monitoring of the results 
of continuing education on the actual practice of physicians. 
Non-Q wave infarction. The differentiation of non-Q 
wave from Q wave infarction is now established as important 
clinically although the ability of the former to predict abso- 
lute transmural distribution of myocardial necrosis is recog- 
nized as flawed. The clinical features and subsequent out- 
come of patients with preservation of QRS integrity but with 
major repolarization abnormalities and elevated creatine 
kinase (CK) MB isoenzyme levels have been well described. 
Most investigators (139) agree that the basic coronary ana- 
tomic feature is usually an incomplete occlusion of the 
infarct-related coronary artery. With a persisting high grade 
stenosis, it is not surprising there is a high rate of subsequent 
myocardial infarction (140). Diltiazem has been documented 
to reduce reinfarction rates (141). However, the continued 
hemodynamic instability of such patients is reflected in a 
significant rate of reinfarction even with diltiazem and a high 
proportion of patients who require early coronary angiogra- 
phy and appropriate revascularization. Few studies have 
examined the role of stress testing for risk stratification after 
non-Q wave myocardial infarction and further data are 
needed. The lack of a direct comparison of outcomes be- 
tween bypass surgery and angioplasty in controlled studies 
hampers our conclusions on advisability of an initial strategy 
of angioplasty or surgery. No direct comparisons of invasive 
treatment versus medical therapy alone in patients with 
non-Q wave infarction have been published. 
Evaluation and therapy of survivors of myocardial infarc- 
tion. A major issue in management of patients with myocar- 
dial infarction is the risk stratification of those who have 
survived the initial hospital admission and are being pre- 
pared for discharge. The three major determinants of late 
prognosis after an acute myocardial infarction include 1) the 
extent of left ventricular dysfunction; 2) the presence and 
severity of residual myocardial ischemia; and 3) ventricular 
arrhythmias. Post-infarction residual ischemia carries a poor 
prognosis but is readily amenable to treatment, usually by 
coronary revascularization. Experimental data in regard to 
the ability of afterload-reducing agents to modify left ven- 
tricular dysfunction are encouraging and clinical studies 
(142) have documented this in post-myocardial infarction 
patients. Additional large clinical trials are evaluating this 
problem. The adverse impact on prognosis of ventricular 
arrhythmias is well recognized (143), but the ability of 
antiarrhythmic therapy to improve survival of symptomatic 
patients is uncertain and also the subject of current large 
scale trials. 
With this uncertainty in mind, the evaluation of survivors 
of myocardial infarction should include a measurement of 
left ventricular function and, in hemodynamically stable 
patients without angina, noninvasive stress testing before 
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hospiral discharge. It is generally accepted that radionuclide a very dynamic process with effective treatment options for 
studies enhance the sensitivity and specificity of stress many patients in 1989. 
testing, but only when they are performed in centers profi- 
cient and experienced in using these complex, quantitative 
imaging modalities. In patients with postinfarction angina. 
particularly if it occurs with minimal exertion, prompt angi- 
ography with a view toward revascularization is indicated 
and most physicians would perform this study before stress 
testing. Signal-averaged ECG studies may be useful in the 
future to identify those patients at risk for malignant ventric- 
ular arrhythmias. Additional tests should be obtained only if 
the information derived is of incremental value beyond data 
obtained on review of the bedside clinical profile (144). 
The question of coronary angiography hqfore hospital 
discharge, particularly in patients who have had successful 
thrombolysis, remains controversial (145). Many investiga- 
tors would compare these patients to patients previously 
categorized as having non-Q wave infarction. particularly if 
myocardial salvage has occurred and there is a residual high 
grade stenosis remaining with demonstrable ischemia in the 
distribution of this infarct-related artery. Additional studies 
will be necessary to establish the role of invasive therapy in 
these asymptomatic patients with a residual high grade 
lesion after successful thrombolytic therapy. 
Sudden Cardiac Death 
Of the almost I million deaths that occur each year in the 
United States, half can be attributed to ischemic heart 
disease, and almost half of these deaths occur suddenly. Our 
ability to detect patients at risk of experiencing sudden 
cardiac death and to effectively treat the underlying ischemic 
heart disease has increased tremendously since 1949 as 
described in the preceding sections of this review. The 
development of cardiac defibrillators and cardiopulmonary 
resuscitation has permitted us to retrieve from certain death 
many such patients both in and out of the hospital. The 
availability of electrophysiologic testing and signal-averaged 
ECGs help us to better understand and treat survivors of 
sudden cardiac death (146-148). In 1949 we had only quini- 
dine to medically treat patients with ischemic heart disease 
who presented with life-threatening ventricular arrhythmias. 
Today we have an extensive array of effective drugs ranging 
(in potency and toxicity) from lidocaine to amiodarone. 
When medical treatment of ventricular arrhythmia proves 
unsuccessful, surgical options are available that include 
ablation of ventricular scars or resection of ventricular 
aneurysm with or without coronary bypass surgery 
(149,150). Implantation of automatic defibrillators is also 
occurring and the future of the ultimate defibrillator holds 
real promise. In short, we have altered an attitude of 
pessimism and futility in our approach to sudden cardiac 
death as a manifestation of coronary artery disease in 1949 to 
Congestive Heart Failure 
Patients with coronary artery disease may manifest con- 
gestive heart failure because of 1) extensive myocardial 
necrosis leading to pump failure: 2) mechanical complica- 
tions of myocardial infarction: and 3) reversible myocardial 
ischemia. The challenge of the clinician managing the patient 
with coronary artery disease and congestive heart failure is 
to determine the relative contribution of these factors to the 
individual patient’s problem. Whereas some cases are obvi- 
ous clinically, others can be frustrating particularly when 
components of ischemia are present (angina, reversible 
perfusion defects) in addition to heart failure. The correct 
classification is important because revascularization may 
enhance survival and relieve symptoms of heart failure if 
there is a concomitant component of reversible ischemia 
(151). 
Early recognition of the mechanical complications of 
myjcardial irfarction is critically important in the setting of 
acute infarction because surgical therapy may dramatically 
improve the outlook. This possibility is particularly likely for 
papillary muscle rupture (152), postinfarction ventricular 
septal defect (153) and, rarely, cardiac perforation (154). 
Risk Factor Control 
A third category of treatment decisions crucial in the 
long-term management of patients with coronary artery 
disease. regardless of the treatment for symptom control or 
enhanced event-free survival, is control of risk factors and 
establishing a rational life style. It is important for the patient 
and family to recognize that such efforts are a life-long 
process and that coronary surgery and angioplasty are only 
palliative forms of therapy. Abundant evidence is available 
to support an aggressive approach to risk factor control, 
although the strength of evidence for benefit with control of 
each risk factor varies. 
Smoking. Avoidance of tobacco is fundamental to the 
long-term success of any therapeutic program in patients 
with coronary artery disease. Enhanced survival after ces- 
sation of smoking has been demonstrated in large samples of 
postmyocardial infarction patients (155), those with angio- 
graphyically documented coronary artery disease (156) and 
others in large population-based studies (157). Behavior 
modification remains a major challenge in dealing with 
patients addicted to tobacco use. 
Hypertension. Control of hypertension has failed to affect 
coronary heart disease mortality directly in large trials (158). 
However, reduced stroke and overall mortality rates empha- 
size the importance of hypertension control (158,159). In 
addition to the benefits of systemic arterial pressure treat- 
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ment, which should initially be non-pharmacologic, some of 
the drugs utilized (calcium channel and beta-blockers) pro- 
vide more direct approaches to relief of associated myocar- 
dial ischemia. 
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